Protocol Ledger

NCT06891833 · Phase II/III · RECRUITING

A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer

Interventional Phase II/III clinical trial protocol NCT06891833 sponsored by Sichuan Baili Pharmaceutical Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-06-05 Enrollment: 985 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06891833
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)985 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06891833
Protocol FieldVerified Registry Value
NCT IdentifierNCT06891833
Consolidated Lead SponsorSichuan Baili Pharmaceutical Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment985 participants (ESTIMATED)
Registered Start Date2025-06-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI